The Greenbrook declared, that Mr. Andrew Crish, 47, had been appointed as its full-time chief operating officer.
Mr. Crish has more than 20 years of varied job experience. Andrew held the position of Vice President of Operations at M2 Orthopedics from December 2021 until his departure from Greenbrook. Before that, from November 2018 to November 2021, he served as National Veterinary Associates’ Vice President of Operations. Andrew worked with DaVita Kidney Care in a number of positions before to joining National Veterinary Associates, including Division Vice President, Division Vice President of Hospital Service, Group Director of Hospital Services, and Director of Regional Operations. From September 2013 to November 2018, Andrew worked at DaVita Kidney Care. Prior to this, from April 2007 until December 2012, Andrew held positions as a Business Operations Manager, Director of Service, and Quality Assurance Leaader at GE Healthcare. In addition, Andrew was employed at BearingPoint, Inc. as a Consultant from October 2006 to October 2007. Andrew was a Surface Warfare Officer, Facilities Manager, and Instructor in the US Navy from May 2000 to October 2006 before he entered the corporate world. From 1996 to 2000, Andrew studied economics for his Bachelor of Science degree at the United States Naval Academy. After that, Andrew continued his study and graduated with an MBA from Northwestern University’s Kellogg School of Management in 2008, with a focus on marketing, finance, management, and strategy.
Mr. Crish signed an employment agreement on March 4, 2024 in connection with his appointment as the company’s full-time Chief Operating Officer. The agreement calls for an annual base pay of US$300,000 plus a target annual performance incentive of up to 40% of base salary. In accordance with the terms of the Employment Agreement, the Board of Directors will be asked to approve a stock option plan award to Mr. Crish in the grant amount of 250,000 Common Shares under the Company’s Equity Incentive Plan. This plan is detailed in Item 6 of the Company’s Annual Report on Form 20-F for the year ended December 31, 2022. In the event that Mr. Crish’s employment is terminated for any reason, he will also be subject to a 12-month non-compete clause as per the terms of the Employment Agreement. An exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, containing a copy of the Employment Agreement, will be filed.
Mr. Crish has also signed the standard indemnity agreement with the company, dated March 4, 2024, in conjunction with his hiring. According to the terms of the indemnity agreement, the company must pay Mr. Crish’s legal costs up front and indemnify him to the maximum degree allowed by law in any proceedings involving him. The indemnity agreement and the agreements other company officers have signed are essentially the same. An exhibit to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, a copy of the indemnity agreement, will be filed.
There is no familial ties between Mr. Crish and any of the company’s directors or executive executives. Mr. Crish was chosen to be an officer of the Company without any agreement or understanding between him and any other parties. Between the Company and Mr. Crish, there are no related party transactions that would need to be disclosed in accordance with Regulation S-K’s Item 404(a).
